US 12,421,269 B2
SGLT2/DPP4 inhibitor and application thereof
Qinghua Mao, Shanghai (CN); Tao Yu, Shanghai (CN); Lu Gan, Shanghai (CN); Yi Li, Shanghai (CN); Chengde Wu, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to CGeneTech (Suzhou, China) CO., Ltd., Jiangsu (CN)
Appl. No. 17/629,527
Filed by CGeneTech (Suzhou, China) CO., Ltd., Jiangsu (CN)
PCT Filed Jul. 24, 2020, PCT No. PCT/CN2020/104521
§ 371(c)(1), (2) Date Jan. 24, 2022,
PCT Pub. No. WO2021/018044, PCT Pub. Date Feb. 4, 2021.
Claims priority of application No. 201910683099.2 (CN), filed on Jul. 26, 2019; application No. 202010119914.5 (CN), filed on Feb. 26, 2020; and application No. 202010572226.4 (CN), filed on Jun. 22, 2020.
Prior Publication US 2022/0242898 A1, Aug. 4, 2022
Int. Cl. C07H 7/06 (2006.01); A61P 3/10 (2006.01)
CPC C07H 7/06 (2013.01) [A61P 3/10 (2018.01)] 9 Claims
 
1. A compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein,
R1 is C1-3 alkyl, which is optionally substituted by 1, 2, or 3 Ra;
R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2, C1-3 alkyl, and C1-3 alkoxy, wherein the C1-3 alkyl and the C1-3 alkoxy are optionally substituted by 1, 2, or 3 Rb;
R5 is selected from H, F, Cl, Br, I, OH, NH2, and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1, 2, or 3 Rc;
R4 is H, F, or Cl, and when R4 is Cl, R2, R3, and R5 are not H at the same time;
Ra, Rb and Rc are each independently selected from F, Cl, Br, I, OH, and NH2.